Medicines, sutezolide and Delpazolide have demonstrated strong antimicrobial activity and a particularly better safety profile compared to linezolid, with potential to replace this current cornerstone in the treatment of tuberculosis resistant to medication. The results were published on July 7 in two articles evaluated by peers in Lancet’s infectious diseasesOne of the main journals in the world in the field of infectious disease medicine. Research partners in Europe included the Radboud University Medical Center in the Netherlands and the German Center for Research on Infections (DZIF), Munichofer, the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, the Center for International Health at the LMU University Hospital and Helmholtz Munich.
The challenge with linezolid
Table of Contents
In 2022, the World Health Organization introduced Lineozid in the context of the BPALM diet, also including bedaquiline, pretomanid and moxifloxacin, such as the 6 -month treatment recommended the standard for patients with multi -resistant TB of the duration of the previous standard 18 months. However, linezolid is problematic for patients because it shows significant toxicity. This prolonged exposure to linezolid, much longer than the use initially planned for bacterial skin infections, frequently leads to serious adverse events such as anemia or optical neuropathy, which are painful for patients, may not resolve fully and may require the cessation of therapy, which limits the success of treatment.
Despite its effectiveness, the linezolid is simply too toxic for many patients. We need to urgently need safer alternatives in this class of antibiotics. “”
PD Dr Norbert Heinrich
The sutezolide and the delpazolide are members of the class of oxazolidinone, such as linezolid, but are less toxic to patients. In two innovative 2B phase 2B clinical trials-Sudocu (Panacea Sinezolid Dose-Finding and Combination Evaluation) and Decode (Panacea Delpazolid Dose and Dose Development)-the two drugs were tested in combination with Bedaquiline, Delamanid and Moxifloxacin, which makes the first trials to use these specific combinations of four. Drugs. Studies, conducted in South Africa and Tanzania, have shown that in patients with pulmonary tuberculosis sensitive to medication, the two drugs are safer and more tolerable for patients than linezolid.
The main results show better results for patients
The sutezolide has proven to be effective with strong antibacterial activity and was well tolerated at all doses tested, without any cases of nerve lesion or blood toxicity – a critical advantage on linezolid. These results suggest that the sutezolid could be a safer alternative for future tuberculosis treatment patterns, in particular in the long term, although no final dose recommendation can still be made.
Delpazolide has improved the effectiveness of the diet combined with bedaquiline, demand and moxifloxacin. One dose once a day of 1,200 mg has reached the desired drug levels for maximum efficiency and was well tolerated over 16 weeks. Above all, no case of nerve lesions or blood -related side effects was observed at this dose. These results position the Delpazolid as a promising alternative to linezolid for future tuberculosis treatment regimes awaiting confirmation in larger studies.
“These results suggest that the two drugs can offer safer treatment options for tuberculosis patients, in particular those who require longer therapy lessons,” noted Dr. Tina Minja, National Pi for the study of decoding Nimr-Mbeya Medical Research Center in Tanzania.
A collaborative global effort
Studies were carried out as part of the Panacea Network (Pan-African Consortium for the assessment of the anti-tuberculosis network), which includes clinical and university partners across Africa and Europe. Southocu and decoration trials were innovative randomized phase 2B clinical studies, in full label and randomized that systematically compared the different dosage levels to assess antibacterial activity, exposure to drugs and safety profiles of Suturezolide and Delpazolide.
Ahead
Publication in Lancet’s infectious diseases highlights the scientific relevance of these results and their potential to shape future tuberculosis treatment strategies. “Seeing fewer side effects with Sutezolid and Delpazolid is an important step – this brings us closer to TB therapies which are both effective and easier to tolerate for patients,” said Dr. Ivan Norena, the head of the medical team at the Institute of Infectious Diseases and Tropical Medicine of the LMU Munich University.
Additional research is now planned to assess the sutezolide and the Delpazolide in larger cohorts and in fully optimized treatment combinations. If the promising results are confirmed, these drugs could play an essential role in the next generation of TB therapies, helping to reduce the side effects related to treatment while maintaining efficiency.
Elin Svensson, principal researcher of the Radboud University Medical Center led data analysis in the two studies. She says, “These results are encouraging and show that there is hope for better drugs for drug resistant tuberculosis. Without collaboration within the Panacea, this would not have been possible in such a short time. It highlights the importance of fighting tuberculosis as a global community.
